BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 8773424)

  • 1. Serum immunoglobulin levels during contraceptive use of depot-medroxyprogesterone acetate in Indian women: a preliminary study.
    Lali P; Chandra L; Gupta RP
    Contraception; 1996 Jun; 53(6):363-5. PubMed ID: 8773424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
    Paiva LC; Pinto-Neto AM; Faundes A
    Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate.
    Kremer J; de Bruijn HW; Hindriks FR
    Contraception; 1980 Oct; 22(4):359-67. PubMed ID: 7449384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
    Garza-Flores J; De la Cruz DL; Valles de Bourges V; Sanchez-Nuncio R; Martinez M; Fuziwara JL; Pérez-Palacios G
    Contraception; 1991 Jul; 44(1):61-71. PubMed ID: 1832626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabecular bone in long-term depot-medroxyprogesterone acetate users.
    Virutamasen P; Wangsuphachart S; Reinprayoon D; Kriengsinyot R; Leepipatpaiboon S; Gua C
    Asia Oceania J Obstet Gynaecol; 1994 Sep; 20(3):269-74. PubMed ID: 7811192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term depot-medroxyprogesterone acetate and bone mineral density.
    Tang OS; Tang G; Yip P; Li B; Fan S
    Contraception; 1999 Jan; 59(1):25-9. PubMed ID: 10342083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.
    Naessen T; Olsson SE; Gudmundson J
    Contraception; 1995 Jul; 52(1):35-9. PubMed ID: 8521712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
    Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
    Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.